Testing effectiveness (Phase 2)Ended earlyNCT01886287
What this trial is testing
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
Who this might be right for
Neuroendocrine Carcinoma
H. Lee Moffitt Cancer Center and Research Institute 2